Blood Cancer Institute Research
This Blood Cancer Institute’s highly collaborative program among experts in basic science and translational and clinical research at Montefiore Einstein Comprehensive Cancer Center is speeding the pathway from lab breakthrough to promising therapies and even cures for blood cancers. The search for new treatment options for people with lymphoma, leukemia, MDS, myeloma and other blood cancers is intensive and fast-paced.
Select Research Published to Date
The robust output of high-impact research publications in the past several years is just one measure of the Institute’s productivity.
Konopleva M, Timothy A, Daver N, et al. Complex I Inhibitor of Oxidative Phosphorylation in Advanced Solid Tumors and Acute Myeloid Leukemia: Phase I Trials. Nat Med. 2022; pre-print: https://doi.org/10.21203/rs.3.rs-1506700/v1
Select Studies Focused on Blood Cancer Outcomes in Historically Underrepresented Groups (URG’s)
Advancing health equity is a priority for Montefiore Einstein Comprehensive Cancer Center, which serves the nation’s most racially and ethnically diverse urban community. To this end, our clinicians and researchers at the Blood Cancer Institute have conducted novel studies to identify the unique effects of blood cancers in people who are Black, Latinx, and of other racial and ethnic minority backgrounds often underrepresented in research and clinical trials. We’ve additionally carried out clinical studies which demonstrate the effectiveness of cell therapies and other specific treatments for leukemias, lymphoma and myeloma in people from these diverse backgrounds.
Examples include:
Landmark demonstration of the effectiveness of cell therapies (CAR-T therapies) in URG and elderly patients with lymphoma:
First demonstration of the effectiveness of COVID-19 vaccines in URG patients with cancer:
Demonstration of transplant and chemotherapy success for myeloma in URG and elderly patients:
Learn More & Join Us in the Search for Cures
More about our fundamental discoveries into the mechanisms of blood cancers is available on our basic research pages. And details about our clinical work, including numerous Investigator-Initiated Trials in blood cancers, appears in our translational and clinical research section.
We welcome you to our initiative, and hope you’ll consider making a donation to help support our work.